NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged […]

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. ("Lineage" or the "Company") (NASDAQ:LINE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Lineage and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE:NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE:SLQT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sable Offshore Corp. ("Sable" or the "Company") (NYSE:SOC).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc.("Replimune" or the "Company") (NASDAQ:REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund ("the Fund" or the "Company") (NASDAQ:RMHIX; RMHVX; RMJAX). Such investors are advised to

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ:NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Neogen and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capricor and certain of its officers and/or